Ellen Lefever - 18 Mar 2026 Form 3 Insider Report for Agomab Therapeutics NV (AGMB)

Reporting relationship
General Counsel
Issuer ticker
AGMB
Reported as of
18 Mar 2026
Net transaction value
$0
Source evidence Original filing metadata and source links for verification. 3 source fields
SEC form
3
Accepted by SEC
18 Mar 2026, 16:01:31 UTC
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Ellen Lefever

Key filing fact

Ellen Lefever filed Form 3 for Agomab Therapeutics NV (AGMB) on 18 Mar 2026.

Key facts

  • This page summarizes Ellen Lefever's Form 3 filing for Agomab Therapeutics NV (AGMB).
  • 0 reported transactions and 6 derivative rows are listed below.
  • Accepted by SEC: 18 Mar 2026, 16:01.

Change

  • No earlier filing in this sequence is available for direct comparison.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0002115887 Primary reporting owner

Lefever Ellen

Relationship
General Counsel
Address
AGOMAB THERAPEUTICS NV, POSTHOFLEI 1/6, ANTWERPEN, BELGIUM
Signature
/s/ Ellen Lefever
Signature date
18 Mar 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AGMB holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
18 Mar 2026
Ownership
Direct
Underlying class
Common shares
Underlying amount
91,256
Exercise price
$2.76
Footnotes
F1, F2, F3
AGMB holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
18 Mar 2026
Ownership
Direct
Underlying class
Common shares
Underlying amount
48,009
Exercise price
$2.76
Footnotes
F1, F2, F3
AGMB holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
18 Mar 2026
Ownership
Direct
Underlying class
Common shares
Underlying amount
54,113
Exercise price
$2.76
Footnotes
F1, F2, F3
AGMB holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
18 Mar 2026
Ownership
Direct
Underlying class
Common shares
Underlying amount
3,832
Exercise price
$2.76
Footnotes
F2, F3, F4
AGMB holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
18 Mar 2026
Ownership
Direct
Underlying class
Common shares
Underlying amount
132,122
Exercise price
$3.18
Footnotes
F2, F3, F4
AGMB holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
18 Mar 2026
Ownership
Direct
Underlying class
Common shares
Underlying amount
127,972
Exercise price
$14.26
Footnotes
F2, F3, F5
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

The shares underlying this option are fully vested and exercisable.

Footnote F2

The common shares may be represented by American Depositary Shares, each of which currently represents one common share.

Footnote F3

The exercise prices are reported in U.S. dollars and reflect the conversion from EUR to USD at an exchange rate of $1.1478 per EUR 1.00 as of March 16, 2026.

Footnote F4

50% of the shares underlying this option vested on February 9, 2026, with the remainder vesting in twenty-four equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

Footnote F5

25% of the shares underlying this option shall vest on February 9, 2027, with the remainder vesting in thirty-six equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

SEC remarks

Exhibit 24 - Power of Attorney

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .